Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$22.97 - $30.58 $288,847 - $384,543
-12,575 Reduced 10.98%
101,961 $2.79 Million
Q3 2023

Nov 14, 2023

SELL
$22.72 - $31.49 $1.52 Million - $2.1 Million
-66,747 Reduced 36.82%
114,536 $2.78 Million
Q2 2023

Dec 13, 2023

BUY
$25.3 - $39.67 $296,187 - $464,416
11,707 Added 6.9%
181,283 $5.03 Million
Q2 2023

Aug 14, 2023

BUY
$25.3 - $39.67 $296,187 - $464,416
11,707 Added 6.9%
181,283 $5.03 Million
Q1 2023

Dec 13, 2023

BUY
$30.21 - $48.1 $1.66 Million - $2.65 Million
55,040 Added 48.05%
169,576 $5.64 Million
Q1 2023

May 15, 2023

SELL
$30.21 - $48.1 $157,092 - $250,120
-5,200 Reduced 2.98%
169,576 $5.64 Million
Q4 2022

Feb 14, 2023

BUY
$22.28 - $38.71 $69,625 - $120,968
3,125 Added 1.82%
174,776 $5.37 Million
Q3 2022

Nov 14, 2022

BUY
$34.2 - $51.69 $945,766 - $1.43 Million
27,654 Added 19.2%
171,651 $5.87 Million
Q2 2022

Aug 15, 2022

BUY
$23.14 - $49.68 $268,771 - $577,033
11,615 Added 8.77%
143,997 $4.99 Million
Q1 2022

May 16, 2022

BUY
$27.77 - $64.4 $57,650 - $133,694
2,076 Added 1.59%
132,382 $5.82 Million
Q4 2021

Feb 14, 2022

BUY
$54.9 - $105.21 $2.69 Million - $5.15 Million
48,969 Added 60.21%
130,306 $8.19 Million
Q3 2021

Nov 15, 2021

SELL
$105.0 - $178.37 $9.25 Million - $15.7 Million
-88,085 Reduced 51.99%
81,337 $8.57 Million
Q2 2021

Aug 16, 2021

BUY
$125.11 - $180.0 $5.04 Million - $7.24 Million
40,249 Added 31.16%
169,422 $30 Million
Q1 2021

May 17, 2021

BUY
$126.27 - $191.71 $16 Million - $24.3 Million
126,691 Added 5104.39%
129,173 $17.2 Million
Q4 2020

Feb 16, 2021

BUY
$81.94 - $135.34 $203,375 - $335,913
2,482 New
2,482 $336,000

Others Institutions Holding ZLAB

About Zai Lab Ltd


  • Ticker ZLAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,908,704
  • Market Cap $2.84B
  • Description
  • Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...
More about ZLAB
Track This Portfolio

Track Polar Capital Holdings PLC Portfolio

Follow Polar Capital Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Polar Capital Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Polar Capital Holdings PLC with notifications on news.